<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967027</url>
  </required_header>
  <id_info>
    <org_study_id>BM V1.0/2020-08-01</org_study_id>
    <nct_id>NCT04967027</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial for Tumor Treating Field for Drug/Radiation Resistant Brain Metastases</brief_title>
  <official_title>Safety and Tolerability of TTFields for Patients With Brain Metastases After the Standard Treatment Fails: a Prospective, Single-center, Single-arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain metastasis is a very common disease with poor prognosis, 20% cancer will develop brain&#xD;
      metastases(BM), up to 40% by autopsy. Great advances have made with the application of&#xD;
      targeting therapy, immunotherapy, chemotherapy, whole brain radiation and radiosurgery,&#xD;
      however, treated patients were finally suffered from drug/radiation resistance and rapid&#xD;
      recurrence. Tumor treating fields (TTFields) is one of the standard combination treatment for&#xD;
      GBM, and some researchers believe that TTFields can effectively inhibit patient-derived lung&#xD;
      adenocarcinoma brain metastasis cells progression in vitro. In this study, the investigator&#xD;
      attempts to evaluate the safety, and tolerability of TTFields in adult participants diagnosed&#xD;
      with Drug/Radiation resistant BM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The treatment-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients who experienced a treatment-related adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>12 months</time_frame>
    <description>Time to progression of patients with brain metastases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients alive at 12 months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>TTFields group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with brain metastases who have been resistant to drug or radiation therapy, to be treated by continuous TTFields treatment using the ASCLU-300 TTF device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ASCLU-300 TTF</intervention_name>
    <description>BM treated by continuous TTFields treatment (ASCLU-300, approved by Chinese FDA)</description>
    <arm_group_label>TTFields group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients are diagnosed as brain metastases by Xiangya Hospital multidisciplinary team;&#xD;
&#xD;
          -  age from 18 to 65 year-old;&#xD;
&#xD;
          -  patients have been progressed from standard therapy (drug/radiation resistance)&#xD;
&#xD;
          -  KPS more than 70 score;&#xD;
&#xD;
          -  anticipated OS more than 3 months;&#xD;
&#xD;
          -  signed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unable to take TTFields more than 18 hours each day;&#xD;
&#xD;
          -  unable to follow-up till progression;&#xD;
&#xD;
          -  the scalp wound is not well healed, the head skin condition is not good, the skull has&#xD;
             a large area defect, or other situations that are not suitable for wearing electrodes&#xD;
&#xD;
          -  pregnant women;&#xD;
&#xD;
          -  last drug within 4 weeks, last radiation within 3 months, take other trials;&#xD;
&#xD;
          -  other heavy diseases like heavy infection;&#xD;
&#xD;
          -  other condition: Such as breastfeeding, installation of cardiac pacemakers, brain&#xD;
             stimulators, severe intracranial edema, increased intracranial pressure leading to&#xD;
             midline structures exceeding 5 mm, optic nerve head edema, disturbance of&#xD;
             consciousness, etc., allergies to conductive coupling agents, gels, etc.&#xD;
&#xD;
          -  blood and biochemical indicators in the following range: A. Liver function impairment:&#xD;
             AST or ALT &gt; 3 times the upper limit of normal; B. Total bilirubin&gt; upper limit of&#xD;
             normal value; C. Renal impairment: serum creatinine&gt;1.7mg /dL (&gt;150 mol/L); D.&#xD;
             Coagulopathy: PT or APTT &gt;1.5 times normal; E. Platelets counts &lt; 100x10^9/L; F.&#xD;
             Absolute neutrophils count &lt; 1x10^9/L; G. Hemoglobin &lt; 100g/L;&#xD;
&#xD;
          -  other conditions physicians not suggest to take the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhixiong Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fangkun Liu, MD</last_name>
    <phone>8615874290600</phone>
    <email>liufangkun@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Zeng, MD</last_name>
    <phone>8618774051768</phone>
    <email>zengyu@csu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhixiong Liu, M.D.</last_name>
      <phone>+8613607318785</phone>
      <email>zhixiongliu@csu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 4, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumor Treating Fields; Brain metastases;</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>due to protect the patients' privacy, we have not yet decided to share each IPD, but we can share IPD once other researchers request upon approval by our Ethics Committee</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

